| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12016-008-8107-9 |
| P698 | PubMed publication ID | 19051065 |
| P50 | author | Ricard Cervera i Segura | Q53547424 |
| Gerard Espinosa | Q60326205 | ||
| Doruk Erkan | Q90968221 | ||
| Silvia Bucciarelli | Q114416206 | ||
| P2860 | cites work | Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines | Q22255576 |
| The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome | Q33216930 | ||
| Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? | Q33330004 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? | Q33369774 | ||
| Antiphospholipid antibodies: lessons from the bench | Q33374666 | ||
| Relapsing catastrophic antiphospholipid syndrome: report of three cases | Q33377259 | ||
| Findings at necropsy in the heart of a patient with anticardiolipin syndrome | Q33434967 | ||
| Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients | Q33502956 | ||
| Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients | Q34435380 | ||
| Long term outcome of catastrophic antiphospholipid syndrome survivors | Q35552789 | ||
| Catastrophic antiphospholipid syndrome: where do we stand? | Q35607279 | ||
| Intravenous immunoglobulin: adverse effects and safe administration | Q36359670 | ||
| The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus | Q36743360 | ||
| Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? | Q36785674 | ||
| The management of the patient with unexpected autoantibody positivity | Q36835109 | ||
| Beta2-glycoprotein I and its clinical significance: from gene sequence to protein levels | Q36940175 | ||
| Lessons from the "Euro-Phospholipid" project | Q37055413 | ||
| Cryptic natural autoantibodies and co-potentiators | Q37192849 | ||
| Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome | Q40083231 | ||
| Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years | Q43549572 | ||
| Steroid-responsive catastrophic antiphospholipid syndrome. | Q44794150 | ||
| Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. | Q45065471 | ||
| Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation | Q45111033 | ||
| Rituximab treatment for resistant antiphospholipid syndrome. | Q46427705 | ||
| The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. | Q51766317 | ||
| Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients | Q56907610 | ||
| Prevention of microvesiculation by adhesion of buds to the mother cell membrane — A possible anticoagulant effect of healthy donor plasma | Q60214111 | ||
| The catastrophic antiphospholipid syndrome | Q68136491 | ||
| Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy | Q77757835 | ||
| [Three episodes of acute multiorgan failure in a woman with secondary antiphospholipid syndrome] | Q77999491 | ||
| Autoantibody explosion in antiphospholipid syndrome | Q80436378 | ||
| Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? | Q80484528 | ||
| Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity | Q80491746 | ||
| Predictive, protective, orphan autoantibodies: the example of anti-phospholipid antibodies | Q81790300 | ||
| Catastrophic antiphospholipid syndrome | Q83282906 | ||
| P433 | issue | 2-3 | |
| P921 | main subject | catastrophic antiphospholipid syndrome | Q5051580 |
| P304 | page(s) | 80-84 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Clinical Reviews in Allergy & Immunology | Q1932354 |
| P1476 | title | Catastrophic antiphospholipid syndrome: treatment, prognosis, and the risk of relapse | |
| P478 | volume | 36 |
| Q94940476 | Antiphospholipid Syndrome |
| Q92986354 | Catastrophic antiphospholipid antibody syndrome as a first manifestation of primary antiphospholipid antibody syndrome in a middle-aged man |
| Q37755290 | Current knowledge regarding Asherson's syndrome |
| Q30235356 | Diagnosis and management of catastrophic antiphospholipid syndrome |
| Q33610593 | Does activation of the FcgammaRIIa play a role in the pathogenesis of the acute lung injury/acute respiratory distress syndrome? |
| Q33438290 | Fatal antiphospholipid syndrome following endoscopic transnasal-transsphenoidal surgery for a pituitary tumor: A case report |
| Q55340119 | The complex treatment including rituximab in the Management of Catastrophic Antiphospholid Syndrome with renal involvement. |
| Q42123111 | The flare up of catastrophic antiphospholipid syndrome: a report of an immunosuppressive withdrawal-induced case. |
| Q37738701 | Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome |
| Q33389337 | Use of rituximab in the antiphospholipid syndrome |
Search more.